Company news: Gilead, Pfizer and Wolters Kluwer
Two potential blockbusters in the pharma pipeline took another step toward reaching market. US regulatory authorities assigned August 2012 PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib. Quad is a single-tablet HIV regimen containing four agents, while tofacitinib is set to become the first oral rheumatoid arthritis drug to enter the injectable RA space. NDAs for both drugs had been submitted earlier this year.
Wolters Kluwer said it completed the sale of its pharma-related marketing & publishing services business to Springer Science+Business Media. The sale, announced in November, is part of Wolters Kluwer's strategy to focus on core health markets through its Wolters Kluwer Health & Pharma Solutions division.